share_log

Delta 9 Reports Financials for Q2 2023

Delta 9 Reports Financials for Q2 2023

達美9號公佈2023年第二季度財務報告
GlobeNewswire ·  2023/08/15 06:00

WINNIPEG, Manitoba, Aug. 14, 2023 (GLOBE NEWSWIRE) -- DELTA 9 CANNABIS INC. (TSX: DN) (OTC: DLTNF) ("Delta 9" or the "Company"), is pleased to announce financial and operating results for the three-month and six-month period ending June 30, 2023.

溫尼伯,馬尼託巴省,2023年8月14日(環球通訊社)--Delta 9大麻公司。多倫多證券交易所股票代碼:DN)(場外交易代碼:DLTNF)(“Delta 9”或“公司”)很高興地宣佈截至2023年6月30日的三個月和六個月期間的財務和經營業績。

Financial Highlights for the three-month period ending June 30, 2023

截至2023年6月30日的三個月財務摘要

  • Net revenue of $18.3 million for the second quarter of 2023, an increase of 4%, from $17.5 million for the same quarter last year.
    • Sequential net revenue increased 8% versus $16.9 million for the three-month period ending March 31, 2023.
  • Gross profit of $5.2 million for the second quarter of 2023, an increase of 12%, from $4.6 million for the same quarter last year.
  • Loss from operations of $(3.5) million for the second quarter of 2023 versus a loss from operations of $(3.4) million for the same quarter last year.
  • Adjusted EBITDA of $1.4 million for the second quarter of 2023 versus an adjusted EBITDA (loss) of $(0.4) million for the same quarter last year.
  • 2023年第二季度淨收入為1830萬美元,同比增長4%,而去年同期為1750萬美元。
    • 在截至2023年3月31日的三個月裡,季度淨收入增長了8%,而去年同期為1690萬美元。
  • 2023年第二季度毛利潤為520萬美元,同比增長12%,而去年同期為460萬美元。
  • 2023年第二季度運營虧損(350萬美元),而去年同期運營虧損(340萬美元)。
  • 2023年第二季度調整後的EBITDA為140萬美元,而去年同期調整後的EBITDA(虧損)為40萬美元。

Financial Highlights for the six-month period ending June 30, 2023

截至2023年6月30日的六個月財務摘要

  • Net revenue of $35.2 million for the first six months of 2023, compared to $30 million for the same period last year.
  • Gross profit of $9.4 million for the first six months of 2023, versus $7.6 million for the same period last year.
  • Loss from operations of $(4.7) million for the first six months of 2023 versus a loss from operations of $(6.4) million for the same period last year.
  • Adjusted EBITDA of $0.8 million for the first six months of 2023 versus an adjusted EBITDA (loss) of $(2.1) million for the same period last year.
  • Cash flows from operations of $2.0 million for the first six months of 2023.
  • 2023年前六個月的淨收入為3520萬美元,而去年同期為3000萬美元。
  • 2023年前六個月的毛利潤為940萬美元,而去年同期為760萬美元。
  • 2023年前六個月的運營虧損為470萬美元,而去年同期的運營虧損為640萬美元。
  • 2023年前六個月調整後的EBITDA為80萬美元,而去年同期調整後的EBITDA(虧損)為210萬美元。
  • 2023年前六個月的運營現金流為200萬美元。
Consolidated Statement of Net Income (Loss) Q3 2022 Q4 2022 Q1 2023 Q2 2023
Revenue $15,693,969 $17,559,647 $16,902,378 $18,252,096
Cost of Sales 13,772,202 14,173,693 12,689,181 13,039,705
Gross Profit Before Unrealized Gain From Changes In Biological Assets 1,921,767 3,385,954 4,213,197 5,212,391
Unrealized gain from changes in fair value of biological assets (Net) 340,602 (2,710,521) 2,135,184 (1,581,124)
Gross Profit $2,262,369 $675,433 $6,348,381 $3,631,267
Expenses
General and Administrative 3,668,708 3,551,472 3,390,234 3,087,652
Sales and Marketing 3,710,471 4,647,409 4,003,020 4,043,689
Share Based Compensation 1,086,858 169,540 167,603 -
Total Operating Expenses $8,466,037 $8,368,421 $7,560,857 $7,131,341
Adjusted EBITDA (Loss) 1 (1,683,018) (1,479,845) (475,595) 1,361,821
Income (Loss) from Operations $(6,203,668) $(7,692,988) $(1,212,476) $(3,500,074)
Other Income/ Expenses (1,470,942) (3,515,430) (1,930,496) 1,460,388
Net Income (Loss) $(7,674,610) $(11,208,418) $(3,142,972) $(2,039,686)
Basic and Diluted Earnings (Loss) Per Share $(0.06) $(0.09) $(0.02) $(0.02)
合併淨收益(損失表) 2022年第三季度 2022年年第四季度 2023年第一季度 2023年第二季度
收入 $15,693,969 $17,559,647 $16,902,378 $18,252,096
銷售成本 13,772,202 14,173,693 12,689,181 13,039,705
生物資產變動未實現收益前的毛利 1921,767 3385,954 4,213,197 5,212,391
生物資產公允價值變動的未實現收益(淨額) 340,602 (2,710,521) 2,135,184 (1,581,124)
毛利 $2262,369 $675,433 $6,348,381 $3631,267
費用
一般和行政 3668708 3551,472 3390234 3087,652
銷售和市場營銷 3710,471 4647,409 4,003,020 4043,689
基於份額的薪酬 1,086,858 169,540 167,603 -
總運營費用 $8,466,037 $8,368,421 $7560,857 $7,131,341
調整後的EBITDA(虧損)1 (1,683,018) (1479,845) (475,595) 1361,821
營業收入(虧損) $(6,203,668) $(7692,988) $(1,212,476) $(3500,074)
其他收入/支出 (1,470,942) (3,515,430) (1,930,496) 1460,388
淨收益(虧損) $(7674,610) $(11,208,418) $(3142,972) $(2039,686))
每股基本收益和稀釋後收益(虧損) $(0.06) $(0.09) $(0.02) $(0.02)


John Arbuthnot, CEO of Delta 9, stated, "Our employees delivered a record second quarter with higher revenues sequentially, and year over year, and with better margins driven by the execution of our strategic plan. We are enjoying the gains from our retail expansion announced last year and from our cost saving initiatives announced in early January 2023. We are delivering on our commitment to grow revenue, drive operating efficiencies, and improve margins and profitability, all while investing in our industry-leading retail brands."


達美航空9公司首席執行官約翰·阿巴斯諾特表示:“由於戰略計劃的執行,我們的員工實現了創紀錄的第二季度營收,收入同比增長,利潤率更高。我們享受著去年宣佈的零售擴張和2023年1月初宣佈的成本節約計劃帶來的收益。我們正在履行增加收入、提高運營效率、提高利潤率和盈利能力的承諾,同時投資於我們行業領先的零售品牌。”

A comprehensive discussion of Delta 9's financial position and results of operations is provided in the Company's Management Discussion & Analysis for the three-month and six-month period ending June 30, 2023 filed on SEDAR on August 14, 2023 and can be found at .

關於達美航空9‘S的財務狀況和經營結果的全面討論載於公司於2023年8月14日提交給SEDAR的截至2023年6月30日的三個月和六個月期間的管理討論與分析中,可在。

2023 Second Quarter Results Conference Call

2023年第二季度業績電話會議

A conference call to discuss the above results is scheduled for August 15, 2022. The conference call will be hosted that day at 11:00 p.m. Eastern Time by John Arbuthnot, Chief Executive Officer, and Jim Lawson, Chief Financial Officer, followed by a question-and-answer period.

討論上述結果的電話會議定於2022年8月15日舉行。電話會議將於當天晚上11點舉行。美國東部時間,首席執行官約翰·阿巴斯諾和首席財務官吉姆·勞森發表講話,隨後進行了問答環節。

DATE: August 15, 2023
TIME: 11:00 pm Eastern Time
Dial in # 1-888-886-7786

REPLAY:

1-877-674-6060
Available until 12:00 midnight Eastern Time, September 15, 2023
Replay passcode: 823449 #
日期: 2023年8月15日
時間: 東部時間晚上11:00
撥入號碼 1-888-886-7786

重播:

1-877-674-6060
開放時間至美國東部時間2023年9月15日午夜12:00
重播密碼: 823449#

For more information contact:

如需更多資訊,請聯繫:

Investor & Media Contact:
Ian Chadsey VP Corporate Affairs
Mobile: 204-898-7722
E-mail: ian.chadsey@delta9.ca

投資者和媒體聯繫方式
伊恩·查德西公司事務副總裁
莫比爾縣電話:204-898-7722
電子郵件郵箱:ian.chadsey@delta9.ca

About Delta 9 Cannabis Inc.

關於Delta 9大麻公司

Delta 9 Cannabis Inc. is a vertically integrated cannabis company focused on bringing the highest quality cannabis products to market. The company sells cannabis products through its wholesale and retail sales channels and sells its cannabis grow pods to other businesses. Delta 9's wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical and recreational cannabis and operates an 95,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9 owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand. Delta 9's shares trade on the Toronto Stock Exchange under the symbol "DN" and on the OTC under the symbol "DLTNF". For more information, please visit .

Delta 9大麻公司是一家垂直整合的大麻公司,專注於將最高質量的大麻產品推向市場。該公司通過批發和零售渠道銷售大麻產品,並將大麻種植豆莢出售給其他企業。Delta 9‘S的全資子公司Delta 9 Bio-Tech Inc.是一家獲得許可的醫療和娛樂用大麻生產商,在加拿大馬尼託巴省的溫尼伯經營著一個95,000平方米英尺的生產設施。Delta 9擁有並運營著Delta 9大麻商店品牌下的零售連鎖店。達美航空9‘S的股票在多倫多證券交易所和場外交易市場的交易代碼分別為“DN”和“DLTNF”。欲瞭解更多資訊,請訪問。

Disclaimer for Forward-Looking Information

對前瞻性資訊的免責聲明

Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company's future business plans and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: (i) the Company's plans to establish a chain of cannabis retail stores across Canada; and (ii) the anticipated production capacity of the Company's planned cannabis processing center. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including all risk factors set forth in the annual information form of Delta 9 dated March 31, 2023 which has been filed on SEDAR. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

本新聞稿中的某些陳述是前瞻性陳述,反映了管理層對公司未來業務計劃和其他事項的期望。前瞻性陳述包括非純粹歷史性的陳述,包括有關對未來的信念、計劃、期望或意圖的陳述。本新聞稿中的前瞻性陳述包括有關以下方面的陳述:(I)該公司計劃在加拿大各地建立一個大麻零售連鎖店;(Ii)該公司計劃的大麻加工中心的預期生產能力。此類陳述會受到風險和不確定因素的影響,這些風險和不確定性可能會導致實際結果、表現或發展與陳述中包含的內容大不相同,包括已在SEDAR上提交的日期為2023年3月31日的Delta 9年度資訊表中列出的所有風險因素。不能保證前瞻性陳述中預期的任何事件都會發生,或者如果發生了,公司將從中獲得什麼好處。敦促讀者在評估本新聞稿中包含的前瞻性陳述時仔細考慮這些因素,並告誡讀者不要過度依賴這些前瞻性陳述,這些前瞻性陳述完全受這些警告性陳述的限制。這些前瞻性陳述是自本新聞稿發佈之日起作出的,除非適用的證券法要求,否則公司沒有任何公開更新任何前瞻性陳述的意圖或義務,無論是由於新資訊、未來事件或結果或其他原因。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論